Literature DB >> 14962189

Peripheral B-cell maturation: the intersection of selection and homeostasis.

Michael P Cancro1.   

Abstract

B cells complete maturation after migrating to the periphery, where they transit several intermediate developmental stages prior to recruitment into the long-lived primary pool. Because B-lineage commitment is not regulated by peripheral pool size and most peripheral B cells are quiescent, the primary factors governing steady-state numbers are the proportion of immature B cells surviving transit through later developmental stages and the longevity of mature B cells themselves. Substantial evidence indicates that the B-cell receptor (BCR) plays an essential role in all these processes, but recent findings suggest a central role for the recently described tumor necrosis factor (TNF) family member, B-lymphocyte stimulator (BLyS). Signaling through one of the BLyS receptors, BLyS receptor 3 (BR3), controls B-cell numbers in two ways: by varying the proportion of cells that complete transitional B-cell development and by serving as the primary determinant of mature B-cell longevity. The recent discovery that BCR signaling is selectively coupled to BR3 expression in a developmentally regulated fashion links BCR- and BLyS-mediated events, suggesting that specificity-based selection and survival may be mechanistically similar processes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14962189     DOI: 10.1111/j.0105-2896.2004.0099.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  40 in total

1.  T cells are required for the peripheral phase of B-cell maturation.

Authors:  Novica M Milićević; Klaus Nohroudi; Zivana Milićević; Hans-Juergen Hedrich; Jürgen Westermann
Journal:  Immunology       Date:  2005-11       Impact factor: 7.397

2.  CXCL13 responsiveness but not CXCR5 expression by late transitional B cells initiates splenic white pulp formation.

Authors:  Harold R Neely; Martin F Flajnik
Journal:  J Immunol       Date:  2015-02-06       Impact factor: 5.422

Review 3.  Characterization of splenic CD21hi T2 B cells.

Authors:  Shilpi Verma; Thomas J Waldschmidt
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 4.  Homeostatic control of B lymphocyte subsets.

Authors:  Jenni E Crowley; Jean L Scholz; William J Quinn; Jason E Stadanlick; John F Treml; Laura S Treml; Yi Hao; Radhika Goenka; Patrick J O'Neill; Andrew H Matthews; Ronald F Parsons; Michael P Cancro
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 5.  Aberrant B-cell homeostasis in chronic GVHD.

Authors:  Stefanie Sarantopoulos; Jerome Ritz
Journal:  Blood       Date:  2015-02-02       Impact factor: 22.113

Review 6.  B cells in chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Bruce R Blazar; Corey Cutler; Jerome Ritz
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-12       Impact factor: 5.742

Review 7.  New roles for the BLyS/BAFF family in antigen-experienced B cell niches.

Authors:  Radhika Goenka; Jean L Scholz; Vishal J Sindhava; Michael P Cancro
Journal:  Cytokine Growth Factor Rev       Date:  2014-01-10       Impact factor: 7.638

8.  Kinetic modeling reveals a common death niche for newly formed and mature B cells.

Authors:  Gitit Shahaf; Michael P Cancro; Ramit Mehr
Journal:  PLoS One       Date:  2010-03-02       Impact factor: 3.240

9.  A novel CD93 polymorphism in non-obese diabetic (NOD) and NZB/W F1 mice is linked to a CD4+ iNKT cell deficient state.

Authors:  Ghazal Zekavat; Raha Mozaffari; Vanessa J Arias; Susan Y Rostami; Armen Badkerhanian; Andrea J Tenner; Kim E Nichols; Ali Naji; Hooman Noorchashm
Journal:  Immunogenetics       Date:  2010-04-13       Impact factor: 2.846

10.  Control of the B cell-intrinsic tolerance programs by ubiquitin ligases Cbl and Cbl-b.

Authors:  Yasuyuki Kitaura; Ihn Kyung Jang; Yan Wang; Yoon-Chi Han; Tetsuya Inazu; Emily J Cadera; Mark Schlissel; Richard R Hardy; Hua Gu
Journal:  Immunity       Date:  2007-05-10       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.